Urinary Biomarker Analysis Reveals Rapid Intrarenal Anti‑inflammatory and Anti-fibrotic Effects of Sparsentan in IgA Nephropathy in the SPARTAN Study
Sparsentan in IgAN: Spotlight on Phase 2 and OLE Clinical Trial Results Evaluating Concomitant Use With SGLT2i
Sparsentan (SPAR) Added to Stable Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Adults With IgA Nephropathy (IgAN) in the Phase 2 SPARTACUS Trial
Population Risk Predictors of Major Adverse Kidney Events Attributed to Focal Segmental Glomerulosclerosis from the CURE-CKD Registry
Engaging Patients for Better Outcomes: Informed Care for IgA Nephropathy
19th International Conference on Endothelin (ET-19)
September 21 - 24, 2025
Charleston
American Society of Nephrology (ASN) Kidney Week 2025
November 6 - 9, 2025
Houston
International Symposium on IgA Nephropathy (IIgANN)
September 17 - 20, 2025
Czech Republic
Effects of Sparsentan after Maximized Angiotensin Receptor Blocker (ARB) Treatment in Patients with IgA Nephropathy (IgAN) in the PROTECT Trial
Clinical Study Outcomes in IgA Nephropathy: A Systematic Literature Review and Narrative Synthesis
Population-Level Risk Factors for Kidney Outcomes in IgA Nephropathy: The CURE-CKD Registry
Long-Term Outcomes in Nephrotic Syndrome by Kidney Biopsy Diagnosis and Proteinuria
15th International Podocyte Conference and 2025 ISGD Meeting
June 10 - 13, 2025
Germany